CVC 150 mg + CVC 300 mg
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
HIV-1-infection
Conditions
HIV-1-infection, Elevated Cardiovascular Risk
Trial Timeline
May 30, 2023 → Jun 19, 2024
NCT ID
NCT05630885About CVC 150 mg + CVC 300 mg
CVC 150 mg + CVC 300 mg is a phase 2 stage product being developed by AbbVie for HIV-1-infection. The current trial status is completed. This product is registered under clinical trial identifier NCT05630885. Target conditions include HIV-1-infection, Elevated Cardiovascular Risk.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05630885 | Phase 2 | Completed |
Competing Products
20 competing products in HIV-1-infection